NEW YORK, Sept. 24, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biotechnology: Global Industry Guide

http://www.reportlinker.com/p0157576/Biotechnology-Global-Industry-Guide...

Biotechnology: Global Industry Guide is an essential resource for top-level data and analysis covering the Biotechnology industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Covers the Global, European and Asia-Pacific markets as well as individual chapters on 5 major markets (France, Germany, Japan, the UK and the US).

* Includes a five-year forecast of the industry

Highlights

The global biotechnology market grew by 7.7% in 2011 to reach a value of $281.7 billion.

In 2016, the global biotechnology market is forecast to have a value of $453.3 billion, an increase of 60.9% since 2011.

Medical/healthcare is the largest segment of the global biotechnology market, accounting for 67.4% of the market's total value.

Americas accounts for 45% of the global biotechnology market value.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The biotechnology market consists of the development, manufacturing and marketing of products based on advanced biotechnology research. The market value reflects revenues of companies within this industry from product sales, licensing fees, royalties and research funding. Any currency conversions used in the creation of this report have been calculated using constant 2011 annual average exchange rates.

TABLE OF CONTENTS

EXECUTIVE SUMMARY 2

Market value 2

Market value forecast 2

Category segmentation 2

Geography segmentation 2

Introduction 21

What is this report about? 21

Who is the target reader? 21

How to use this report 21

Definitions 21

Global Biotechnology 22

Market Overview 22

Market Data 23

Market Segmentation 24

Market outlook 26

Five forces analysis 27

Biotechnology in Asia-Pacific 33

Market Overview 33

Market Data 34

Market Segmentation 35

Market outlook 37

Five forces analysis 38

Biotechnology in Europe 44

Market Overview 44

Market Data 45

Market Segmentation 46

Market outlook 48

Five forces analysis 49

Biotechnology in France 55

Market Overview 55

Market Data 56

Market Segmentation 57

Market outlook 59

Five forces analysis 60

Macroeconomic indicators 66

Biotechnology in Germany 68

Market Overview 68

Market Data 69

Market Segmentation 70

Market outlook 72

Five forces analysis 73

Macroeconomic indicators 79

Biotechnology in Italy 81

Market Overview 81

Market Data 82

Market Segmentation 83

Market outlook 85

Five forces analysis 86

Macroeconomic indicators 92

Biotechnology in Japan 94

Market Overview 94

Market Data 95

Market Segmentation 96

Market outlook 98

Five forces analysis 99

Macroeconomic indicators 105

Biotechnology in Belgium 107

Market Overview 107

Market Data 108

Market Segmentation 109

Market outlook 111

Five forces analysis 112

Macroeconomic indicators 118

Biotechnology in Canada 120

Market Overview 120

Market Data 121

Market Segmentation 122

Market outlook 124

Five forces analysis 125

Macroeconomic indicators 131

Biotechnology in China 133

Market Overview 133

Market Data 134

Market Segmentation 135

Market outlook 137

Five forces analysis 138

Macroeconomic indicators 144

Biotechnology in The Netherlands 146

Market Overview 146

Market Data 147

Market Segmentation 148

Market outlook 150

Five forces analysis 151

Macroeconomic indicators 157

Biotechnology in Spain 159

Market Overview 159

Market Data 160

Market Segmentation 161

Market outlook 163

Five forces analysis 164

Macroeconomic indicators 170

Biotechnology in The United Kingdom 172

Market Overview 172

Market Data 173

Market Segmentation 174

Market outlook 176

Five forces analysis 177

Macroeconomic indicators 183

Biotechnology in The United States 185

Market Overview 185

Market Data 186

Market Segmentation 187

Market outlook 189

Five forces analysis 190

Macroeconomic indicators 196

Company Profiles 198

Leading companies 198

Appendix 272

Methodology 272

LIST OF TABLES

Table 1: Global biotechnology market value: $ billion, 2007–11 23

Table 2: Global biotechnology market category segmentation: $ billion, 2011 24

Table 3: Global biotechnology market geography segmentation: $ billion, 2011 25

Table 4: Global biotechnology market value forecast: $ billion, 2011–16 26

Table 5: Asia-Pacific biotechnology market value: $ billion, 2007–11 34

Table 6: Asia–Pacific biotechnology market category segmentation: $ billion, 2011 35

Table 7: Asia–Pacific biotechnology market geography segmentation: $ billion, 2011 36

Table 8: Asia-Pacific biotechnology market value forecast: $ billion, 2011–16 37

Table 9: Europe biotechnology market value: $ billion, 2007–11 45

Table 10: Europe biotechnology market category segmentation: $ billion, 2011 46

Table 11: Europe biotechnology market geography segmentation: $ billion, 2011 47

Table 12: Europe biotechnology market value forecast: $ billion, 2011–16 48

Table 13: France biotechnology market value: $ billion, 2007–11 56

Table 14: France biotechnology market category segmentation: $ billion, 2011 57

Table 15: France biotechnology market geography segmentation: $ billion, 2011 58

Table 16: France biotechnology market value forecast: $ billion, 2011–16 59

Table 17: France size of population (million), 2007–11 66

Table 18: France gdp (constant 2000 prices, $ billion), 2007–11 66

Table 19: France gdp (current prices, $ billion), 2007–11 66

Table 20: France inflation, 2007–11 67

Table 21: France consumer price index (absolute), 2007–11 67

Table 22: France exchange rate, 2007–11 67

Table 23: Germany biotechnology market value: $ billion, 2007–11 69

Table 24: Germany biotechnology market category segmentation: $ billion, 2011 70

Table 25: Germany biotechnology market geography segmentation: $ billion, 2011 71

Table 26: Germany biotechnology market value forecast: $ billion, 2011–16 72

Table 27: Germany size of population (million), 2007–11 79

Table 28: Germany gdp (constant 2000 prices, $ billion), 2007–11 79

Table 29: Germany gdp (current prices, $ billion), 2007–11 79

Table 30: Germany inflation, 2007–11 80

Table 31: Germany consumer price index (absolute), 2007–11 80

Table 32: Germany exchange rate, 2007–11 80

Table 33: Italy biotechnology market value: $ billion, 2007–11 82

Table 34: Italy biotechnology market category segmentation: $ billion, 2011 83

Table 35: Italy biotechnology market geography segmentation: $ billion, 2011 84

Table 36: Italy biotechnology market value forecast: $ billion, 2011–16 85

Table 37: Italy size of population (million), 2007–11 92

Table 38: Italy gdp (constant 2000 prices, $ billion), 2007–11 92

Table 39: Italy gdp (current prices, $ billion), 2007–11 92

Table 40: Italy inflation, 2007–11 93

Table 41: Italy consumer price index (absolute), 2007–11 93

Table 42: Italy exchange rate, 2007–11 93

Table 43: Japan biotechnology market value: $ billion, 2007–11 95

Table 44: Japan biotechnology market category segmentation: $ billion, 2011 96

Table 45: Japan biotechnology market geography segmentation: $ billion, 2011 97

Table 46: Japan biotechnology market value forecast: $ billion, 2011–16 98

Table 47: Japan size of population (million), 2007–11 105

Table 48: Japan gdp (constant 2000 prices, $ billion), 2007–11 105

Table 49: Japan gdp (current prices, $ billion), 2007–11 105

Table 50: Japan inflation, 2007–11 106

Table 51: Japan consumer price index (absolute), 2007–11 106

Table 52: Japan exchange rate, 2007–11 106

Table 53: Belgium biotechnology market value: $ billion, 2007–11 108

Table 54: Belgium biotechnology market category segmentation: $ billion, 2011 109

Table 55: Belgium biotechnology market geography segmentation: $ billion, 2011 110

Table 56: Belgium biotechnology market value forecast: $ billion, 2011–16 111

Table 57: Belgium size of population (million), 2007–11 118

Table 58: Belgium gdp (constant 2000 prices, $ billion), 2007–11 118

Table 59: Belgium gdp (current prices, $ billion), 2007–11 118

Table 60: Belgium inflation, 2007–11 119

Table 61: Belgium consumer price index (absolute), 2007–11 119

Table 62: Belgium exchange rate, 2007–11 119

Table 63: Canada biotechnology market value: $ billion, 2007–11 121

Table 64: Canada biotechnology market category segmentation: $ billion, 2011 122

Table 65: Canada biotechnology market geography segmentation: $ billion, 2011 123

Table 66: Canada biotechnology market value forecast: $ billion, 2011–16 124

Table 67: Canada size of population (million), 2007–11 131

Table 68: Canada gdp (constant 2000 prices, $ billion), 2007–11 131

Table 69: Canada gdp (current prices, $ billion), 2007–11 131

Table 70: Canada inflation, 2007–11 132

Table 71: Canada consumer price index (absolute), 2007–11 132

Table 72: Canada exchange rate, 2007–11 132

Table 73: China biotechnology market value: $ billion, 2007–11 134

Table 74: China biotechnology market category segmentation: $ billion, 2011 135

Table 75: China biotechnology market geography segmentation: $ billion, 2011 136

Table 76: China biotechnology market value forecast: $ billion, 2011–16 137

Table 77: China size of population (million), 2007–11 144

Table 78: China gdp (constant 2000 prices, $ billion), 2007–11 144

Table 79: China gdp (current prices, $ billion), 2007–11 144

Table 80: China inflation, 2007–11 145

Table 81: China consumer price index (absolute), 2007–11 145

Table 82: China exchange rate, 2007–11 145

Table 83: Netherlands biotechnology market value: $ million, 2007–11 147

Table 84: Netherlands biotechnology market category segmentation: $ million, 2011 148

Table 85: Netherlands biotechnology market geography segmentation: $ billion, 2011 149

Table 86: Netherlands biotechnology market value forecast: $ million, 2011–16 150

Table 87: Netherlands size of population (million), 2007–11 157

Table 88: Netherlands gdp (constant 2000 prices, $ billion), 2007–11 157

Table 89: Netherlands gdp (current prices, $ billion), 2007–11 157

Table 90: Netherlands inflation, 2007–11 158

Table 91: Netherlands consumer price index (absolute), 2007–11 158

Table 92: Netherlands exchange rate, 2007–11 158

Table 93: Spain biotechnology market value: $ billion, 2007–11 160

Table 94: Spain biotechnology market category segmentation: $ billion, 2011 161

Table 95: Spain biotechnology market geography segmentation: $ billion, 2011 162

Table 96: Spain biotechnology market value forecast: $ billion, 2011–16 163

Table 97: Spain size of population (million), 2007–11 170

Table 98: Spain gdp (constant 2000 prices, $ billion), 2007–11 170

Table 99: Spain gdp (current prices, $ billion), 2007–11 170

Table 100: Spain inflation, 2007–11 171

Table 101: Spain consumer price index (absolute), 2007–11 171

Table 102: Spain exchange rate, 2007–11 171

Table 103: United Kingdom biotechnology market value: $ billion, 2007–11 173

Table 104: United Kingdom biotechnology market category segmentation: $ billion, 2011 174

Table 105: United Kingdom biotechnology market geography segmentation: $ billion, 2011 175

Table 106: United Kingdom biotechnology market value forecast: $ billion, 2011–16 176

Table 107: United Kingdom size of population (million), 2007–11 183

Table 108: United Kingdom gdp (constant 2000 prices, $ billion), 2007–11 183

Table 109: United Kingdom gdp (current prices, $ billion), 2007–11 183

Table 110: United Kingdom inflation, 2007–11 184

Table 111: United Kingdom consumer price index (absolute), 2007–11 184

Table 112: United Kingdom exchange rate, 2007–11 184

Table 113: United States biotechnology market value: $ billion, 2007–11 186

Table 114: United States biotechnology market category segmentation: $ billion, 2011 187

Table 115: United States biotechnology market geography segmentation: $ billion, 2011 188

Table 116: United States biotechnology market value forecast: $ billion, 2011–16 189

Table 117: United States size of population (million), 2007–11 196

Table 118: United States gdp (constant 2000 prices, $ billion), 2007–11 196

Table 119: United States gdp (current prices, $ billion), 2007–11 196

Table 120: United States inflation, 2007–11 197

Table 121: United States consumer price index (absolute), 2007–11 197

Table 122: United States exchange rate, 2007–11 197

Table 123: Amgen, Inc.: key facts 198

Table 124: Amgen, Inc.: key financials ($) 199

Table 125: Amgen, Inc.: key financial ratios 199

Table 126: Covance Inc.: key facts 201

Table 127: Covance Inc.: key financials ($) 202

Table 128: Covance Inc.: key financial ratios 202

Table 129: Merck & Co., Inc.: key facts 204

Table 130: Merck & Co., Inc.: key financials ($) 205

Table 131: Merck & Co., Inc.: key financial ratios 205

Table 132: F. Hoffmann-La Roche Ltd: key facts 207

Table 133: F. Hoffmann-La Roche Ltd: key financials ($) 208

Table 134: F. Hoffmann-La Roche Ltd: key financials (CHF) 208

Table 135: F. Hoffmann-La Roche Ltd: key financial ratios 208

Table 136: Astellas Pharma Inc.: key facts 210

Table 137: Astellas Pharma Inc.: key financials ($) 211

Table 138: Astellas Pharma Inc.: key financials (¥) 211

Table 139: Astellas Pharma Inc.: key financial ratios 211

Table 140: Kyowa Hakko Kirin Co., Ltd.: key facts 213

Table 141: Kyowa Hakko Kirin Co., Ltd.: key financials ($) 214

Table 142: Kyowa Hakko Kirin Co., Ltd.: key financials (¥) 214

Table 143: Kyowa Hakko Kirin Co., Ltd.: key financial ratios 214

Table 144: Mitsubishi Tanabe Pharma Corporation: key facts 216

Table 145: Mitsubishi Tanabe Pharma Corporation: key financials ($) 216

Table 146: Mitsubishi Tanabe Pharma Corporation: key financials (¥) 217

Table 147: Mitsubishi Tanabe Pharma Corporation: key financial ratios 217

Table 148: AstraZeneca PLC: key facts 219

Table 149: AstraZeneca PLC: key financials ($) 220

Table 150: AstraZeneca PLC: key financial ratios 220

Table 151: Boehringer Ingelheim GmbH: key facts 222

Table 152: Boehringer Ingelheim GmbH: key financials ($) 223

Table 153: Boehringer Ingelheim GmbH: key financials (€) 223

Table 154: Boehringer Ingelheim GmbH: key financial ratios 223

Table 155: BioAlliance Pharma SA: key facts 225

Table 156: bioMerieux SA: key facts 226

Table 157: bioMerieux SA: key financials ($) 227

Table 158: bioMerieux SA: key financials (€) 227

Table 159: bioMerieux SA: key financial ratios 227

Table 160: Transgene S.A.: key facts 229

Table 161: Transgene S.A.: key financials ($) 230

Table 162: Transgene S.A.: key financial ratios 230

Table 163: MorphoSys AG: key facts 232

Table 164: MorphoSys AG: key financials ($) 233

Table 165: MorphoSys AG: key financials (€) 233

Table 166: MorphoSys AG: key financial ratios 233

Table 167: Gentium S.p.A.: key facts 235

Table 168: Gentium S.p.A.: key financials ($) 236

Table 169: Gentium S.p.A.: key financials (€) 236

Table 170: Gentium S.p.A.: key financial ratios 236

Table 171: Menarini Group, The: key facts 238

Table 172: Zambon Company S.p.A.: key facts 239

Table 173: Daiichi Sankyo Co., Ltd.: key facts 240

Table 174: Daiichi Sankyo Co., Ltd.: key financials ($) 241

Table 175: Daiichi Sankyo Co., Ltd.: key financials (¥) 241

Table 176: Daiichi Sankyo Co., Ltd.: key financial ratios 241

Table 177: Novartis AG: key facts 243

Table 178: Novartis AG: key financials ($) 244

Table 179: Novartis AG: key financial ratios 244

Table 180: Sanofi SA: key facts 246

Table 181: Sanofi SA: key financials ($) 247

Table 182: Sanofi SA: key financials (€) 247

Table 183: Sanofi SA: key financial ratios 247

Table 184: ThromboGenics NV: key facts 249

Table 185: Baxter International Inc.: key facts 250

Table 186: Baxter International Inc.: key financials ($) 251

Table 187: Baxter International Inc.: key financial ratios 251

Table 188: Sinovac Biotech: key facts 253

Table 189: Sinovac Biotech: key financials ($) 253

Table 190: Sinovac Biotech: key financial ratios 254

Table 191: Actelion Ltd: key facts 256

Table 192: Actelion Ltd: key financials ($) 257

Table 193: Actelion Ltd: key financials (CHF) 257

Table 194: Actelion Ltd: key financial ratios 257

Table 195: Biogen Idec, Inc.: key facts 259

Table 196: Biogen Idec, Inc.: key financials ($) 260

Table 197: Biogen Idec, Inc.: key financial ratios 260

Table 198: Crucell N.V.: key facts 262

Table 199: Esteve Group: key facts 263

Table 200: Grifols SA: key facts 264

Table 201: Grifols SA: key financials ($) 265

Table 202: Grifols SA: key financials (€) 265

Table 203: Grifols SA: key financial ratios 265

Table 204: Zeltia, S.A.: key facts 267

Table 205: GE Healthcare: key facts 268

Table 206: Novartis AG: key facts 269

Table 207: Novartis AG: key financials ($) 270

Table 208: Novartis AG: key financial ratios 270

LIST OF FIGURES

Figure 1: Global biotechnology market value: $ billion, 2007–11 23

Figure 2: Global biotechnology market category segmentation: % share, by value, 2011 24

Figure 3: Global biotechnology market geography segmentation: % share, by value, 2011 25

Figure 4: Global biotechnology market value forecast: $ billion, 2011–16 26

Figure 5: Forces driving competition in the global biotechnology market, 2011 27

Figure 6: Drivers of buyer power in the global biotechnology market, 2011 28

Figure 7: Drivers of supplier power in the global biotechnology market, 2011 29

Figure 8: Factors influencing the likelihood of new entrants in the global biotechnology market, 2011 30

Figure 9: Factors influencing the threat of substitutes in the global biotechnology market, 2011 31

Figure 10: Drivers of degree of rivalry in the global biotechnology market, 2011 32

Figure 11: Asia-Pacific biotechnology market value: $ billion, 2007–11 34

Figure 12: Asia–Pacific biotechnology market category segmentation: % share, by value, 2011 35

Figure 13: Asia–Pacific biotechnology market geography segmentation: % share, by value, 2011 36

Figure 14: Asia-Pacific biotechnology market value forecast: $ billion, 2011–16 37

Figure 15: Forces driving competition in the biotechnology market in Asia-Pacific, 2011 38

Figure 16: Drivers of buyer power in the biotechnology market in Asia-Pacific, 2011 39

Figure 17: Drivers of supplier power in the biotechnology market in Asia-Pacific, 2011 40

Figure 18: Factors influencing the likelihood of new entrants in the biotechnology market in Asia-Pacific, 2011 41

Figure 19: Factors influencing the threat of substitutes in the biotechnology market in Asia-Pacific, 2011 42

Figure 20: Drivers of degree of rivalry in the biotechnology market in Asia-Pacific, 2011 43

Figure 21: Europe biotechnology market value: $ billion, 2007–11 45

Figure 22: Europe biotechnology market category segmentation: % share, by value, 2011 46

Figure 23: Europe biotechnology market geography segmentation: % share, by value, 2011 47

Figure 24: Europe biotechnology market value forecast: $ billion, 2011–16 48

Figure 25: Forces driving competition in the biotechnology market in Europe, 2011 49

Figure 26: Drivers of buyer power in the biotechnology market in Europe, 2011 50

Figure 27: Drivers of supplier power in the biotechnology market in Europe, 2011 51

Figure 28: Factors influencing the likelihood of new entrants in the biotechnology market in Europe, 2011 52

Figure 29: Factors influencing the threat of substitutes in the biotechnology market in Europe, 2011 53

Figure 30: Drivers of degree of rivalry in the biotechnology market in Europe, 2011 54

Figure 31: France biotechnology market value: $ billion, 2007–11 56

Figure 32: France biotechnology market category segmentation: % share, by value, 2011 57

Figure 33: France biotechnology market geography segmentation: % share, by value, 2011 58

Figure 34: France biotechnology market value forecast: $ billion, 2011–16 59

Figure 35: Forces driving competition in the biotechnology market in France, 2011 60

Figure 36: Drivers of buyer power in the biotechnology market in France, 2011 61

Figure 37: Drivers of supplier power in the biotechnology market in France, 2011 62

Figure 38: Factors influencing the likelihood of new entrants in the biotechnology market in France, 2011 63

Figure 39: Factors influencing the threat of substitutes in the biotechnology market in France, 2011 64

Figure 40: Drivers of degree of rivalry in the biotechnology market in France, 2011 65

Figure 41: Germany biotechnology market value: $ billion, 2007–11 69

Figure 42: Germany biotechnology market category segmentation: % share, by value, 2011 70

Figure 43: Germany biotechnology market geography segmentation: % share, by value, 2011 71

Figure 44: Germany biotechnology market value forecast: $ billion, 2011–16 72

Figure 45: Forces driving competition in the biotechnology market in Germany, 2011 73

Figure 46: Drivers of buyer power in the biotechnology market in Germany, 2011 74

Figure 47: Drivers of supplier power in the biotechnology market in Germany, 2011 75

Figure 48: Factors influencing the likelihood of new entrants in the biotechnology market in Germany, 2011 76

Figure 49: Factors influencing the threat of substitutes in the biotechnology market in Germany, 2011 77

Figure 50: Drivers of degree of rivalry in the biotechnology market in Germany, 2011 78

Figure 51: Italy biotechnology market value: $ billion, 2007–11 82

Figure 52: Italy biotechnology market category segmentation: % share, by value, 2011 83

Figure 53: Italy biotechnology market geography segmentation: % share, by value, 2011 84

Figure 54: Italy biotechnology market value forecast: $ billion, 2011–16 85

Figure 55: Forces driving competition in the biotechnology market in Italy, 2011 86

Figure 56: Drivers of buyer power in the biotechnology market in Italy, 2011 87

Figure 57: Drivers of supplier power in the biotechnology market in Italy, 2011 88

Figure 58: Factors influencing the likelihood of new entrants in the biotechnology market in Italy, 2011 89

Figure 59: Factors influencing the threat of substitutes in the biotechnology market in Italy, 2011 90

Figure 60: Drivers of degree of rivalry in the biotechnology market in Italy, 2011 91

Figure 61: Japan biotechnology market value: $ billion, 2007–11 95

Figure 62: Japan biotechnology market category segmentation: % share, by value, 2011 96

Figure 63: Japan biotechnology market geography segmentation: % share, by value, 2011 97

Figure 64: Japan biotechnology market value forecast: $ billion, 2011–16 98

Figure 65: Forces driving competition in the biotechnology market in Japan, 2011 99

Figure 66: Drivers of buyer power in the biotechnology market in Japan, 2011 100

Figure 67: Drivers of supplier power in the biotechnology market in Japan, 2011 101

Figure 68: Factors influencing the likelihood of new entrants in the biotechnology market in Japan, 2011 102

Figure 69: Factors influencing the threat of substitutes in the biotechnology market in Japan, 2011 103

Figure 70: Drivers of degree of rivalry in the biotechnology market in Japan, 2011 104

Figure 71: Belgium biotechnology market value: $ billion, 2007–11 108

Figure 72: Belgium biotechnology market category segmentation: % share, by value, 2011 109

Figure 73: Belgium biotechnology market geography segmentation: % share, by value, 2011 110

Figure 74: Belgium biotechnology market value forecast: $ billion, 2011–16 111

Figure 75: Forces driving competition in the biotechnology market in Belgium, 2011 112

Figure 76: Drivers of buyer power in the biotechnology market in Belgium, 2011 113

Figure 77: Drivers of supplier power in the biotechnology market in Belgium, 2011 114

Figure 78: Factors influencing the likelihood of new entrants in the biotechnology market in Belgium, 2011 115

Figure 79: Factors influencing the threat of substitutes in the biotechnology market in Belgium, 2011 116

Figure 80: Drivers of degree of rivalry in the biotechnology market in Belgium, 2011 117

Figure 81: Canada biotechnology market value: $ billion, 2007–11 121

Figure 82: Canada biotechnology market category segmentation: % share, by value, 2011 122

Figure 83: Canada biotechnology market geography segmentation: % share, by value, 2011 123

Figure 84: Canada biotechnology market value forecast: $ billion, 2011–16 124

Figure 85: Forces driving competition in the biotechnology market in Canada, 2011 125

Figure 86: Drivers of buyer power in the biotechnology market in Canada, 2011 126

Figure 87: Drivers of supplier power in the biotechnology market in Canada, 2011 127

Figure 88: Factors influencing the likelihood of new entrants in the biotechnology market in Canada, 2011 128

Figure 89: Factors influencing the threat of substitutes in the biotechnology market in Canada, 2011 129

Figure 90: Drivers of degree of rivalry in the biotechnology market in Canada, 2011 130

Figure 91: China biotechnology market value: $ billion, 2007–11 134

Figure 92: China biotechnology market category segmentation: % share, by value, 2011 135

Figure 93: China biotechnology market geography segmentation: % share, by value, 2011 136

Figure 94: China biotechnology market value forecast: $ billion, 2011–16 137

Figure 95: Forces driving competition in the biotechnology market in China, 2011 138

Figure 96: Drivers of buyer power in the biotechnology market in China, 2011 139

Figure 97: Drivers of supplier power in the biotechnology market in China, 2011 140

Figure 98: Factors influencing the likelihood of new entrants in the biotechnology market in China, 2011 141

Figure 99: Factors influencing the threat of substitutes in the biotechnology market in China, 2011 142

Figure 100: Drivers of degree of rivalry in the biotechnology market in China, 2011 143

Figure 101: Netherlands biotechnology market value: $ million, 2007–11 147

Figure 102: Netherlands biotechnology market category segmentation: % share, by value, 2011 148

Figure 103: Netherlands biotechnology market geography segmentation: % share, by value, 2011 149

Figure 104: Netherlands biotechnology market value forecast: $ million, 2011–16 150

Figure 105: Forces driving competition in the biotechnology market in the Netherlands, 2011 151

Figure 106: Drivers of buyer power in the biotechnology market in the Netherlands, 2011 152

Figure 107: Drivers of supplier power in the biotechnology market in the Netherlands, 2011 153

Figure 108: Factors influencing the likelihood of new entrants in the biotechnology market in the Netherlands, 2011 154

Figure 109: Factors influencing the threat of substitutes in the biotechnology market in the Netherlands, 2011 155

Figure 110: Drivers of degree of rivalry in the biotechnology market in the Netherlands, 2011 156

Figure 111: Spain biotechnology market value: $ billion, 2007–11 160

Figure 112: Spain biotechnology market category segmentation: % share, by value, 2011 161

Figure 113: Spain biotechnology market geography segmentation: % share, by value, 2011 162

Figure 114: Spain biotechnology market value forecast: $ billion, 2011–16 163

Figure 115: Forces driving competition in the biotechnology market in Spain, 2011 164

Figure 116: Drivers of buyer power in the biotechnology market in Spain, 2011 165

Figure 117: Drivers of supplier power in the biotechnology market in Spain, 2011 166

Figure 118: Factors influencing the likelihood of new entrants in the biotechnology market in Spain, 2011 167

Figure 119: Factors influencing the threat of substitutes in the biotechnology market in Spain, 2011 168

Figure 120: Drivers of degree of rivalry in the biotechnology market in Spain, 2011 169

Figure 121: United Kingdom biotechnology market value: $ billion, 2007–11 173

Figure 122: United Kingdom biotechnology market category segmentation: % share, by value, 2011 174

Figure 123: United Kingdom biotechnology market geography segmentation: % share, by value, 2011 175

Figure 124: United Kingdom biotechnology market value forecast: $ billion, 2011–16 176

Figure 125: Forces driving competition in the biotechnology market in the United Kingdom, 2011 177

Figure 126: Drivers of buyer power in the biotechnology market in the United Kingdom, 2011 178

Figure 127: Drivers of supplier power in the biotechnology market in the United Kingdom, 2011 179

Figure 128: Factors influencing the likelihood of new entrants in the biotechnology market in the United Kingdom, 2011 180

Figure 129: Factors influencing the threat of substitutes in the biotechnology market in the United Kingdom, 2011 181

Figure 130: Drivers of degree of rivalry in the biotechnology market in the United Kingdom, 2011 182

Figure 131: United States biotechnology market value: $ billion, 2007–11 186

Figure 132: United States biotechnology market category segmentation: % share, by value, 2011 187

Figure 133: United States biotechnology market geography segmentation: % share, by value, 2011 188

Figure 134: United States biotechnology market value forecast: $ billion, 2011–16 189

Figure 135: Forces driving competition in the biotechnology market in the United States, 2011 190

Figure 136: Drivers of buyer power in the biotechnology market in the United States, 2011 191

Figure 137: Drivers of supplier power in the biotechnology market in the United States, 2011 192

Figure 138: Factors influencing the likelihood of new entrants in the biotechnology market in the United States, 2011 193

Figure 139: Factors influencing the threat of substitutes in the biotechnology market in the United States, 2011 194

Figure 140: Drivers of degree of rivalry in the biotechnology market in the United States, 2011 195

Figure 141: Amgen, Inc.: revenues & profitability 200

Figure 142: Amgen, Inc.: assets & liabilities 200

Figure 143: Covance Inc.: revenues & profitability 203

Figure 144: Covance Inc.: assets & liabilities 203

Figure 145: Merck & Co., Inc.: revenues & profitability 206

Figure 146: Merck & Co., Inc.: assets & liabilities 206

Figure 147: F. Hoffmann-La Roche Ltd: revenues & profitability 209

Figure 148: F. Hoffmann-La Roche Ltd: assets & liabilities 209

Figure 149: Astellas Pharma Inc.: revenues & profitability 212

Figure 150: Astellas Pharma Inc.: assets & liabilities 212

Figure 151: Kyowa Hakko Kirin Co., Ltd.: revenues & profitability 215

Figure 152: Kyowa Hakko Kirin Co., Ltd.: assets & liabilities 215

Figure 153: Mitsubishi Tanabe Pharma Corporation: revenues & profitability 217

Figure 154: Mitsubishi Tanabe Pharma Corporation: assets & liabilities 218

Figure 155: AstraZeneca PLC: revenues & profitability 221

Figure 156: AstraZeneca PLC: assets & liabilities 221

Figure 157: Boehringer Ingelheim GmbH: revenues & profitability 224

Figure 158: Boehringer Ingelheim GmbH: assets & liabilities 224

Figure 159: bioMerieux SA: revenues & profitability 228

Figure 160: bioMerieux SA: assets & liabilities 228

Figure 161: Transgene S.A.: revenues & profitability 231

Figure 162: Transgene S.A.: assets & liabilities 231

Figure 163: MorphoSys AG: revenues & profitability 234

Figure 164: MorphoSys AG: assets & liabilities 234

Figure 165: Gentium S.p.A.: revenues & profitability 237

Figure 166: Gentium S.p.A.: assets & liabilities 237

Figure 167: Daiichi Sankyo Co., Ltd.: revenues & profitability 242

Figure 168: Daiichi Sankyo Co., Ltd.: assets & liabilities 242

Figure 169: Novartis AG: revenues & profitability 244

Figure 170: Novartis AG: assets & liabilities 245

Figure 171: Sanofi SA: revenues & profitability 248

Figure 172: Sanofi SA: assets & liabilities 248

Figure 173: Baxter International Inc.: revenues & profitability 251

Figure 174: Baxter International Inc.: assets & liabilities 252

Figure 175: Sinovac Biotech: revenues & profitability 254

Figure 176: Sinovac Biotech: assets & liabilities 255

Figure 177: Actelion Ltd: revenues & profitability 258

Figure 178: Actelion Ltd: assets & liabilities 258

Figure 179: Biogen Idec, Inc.: revenues & profitability 261

Figure 180: Biogen Idec, Inc.: assets & liabilities 261

Figure 181: Grifols SA: revenues & profitability 266

Figure 182: Grifols SA: assets & liabilities 266

Figure 183: Novartis AG: revenues & profitability 270

Figure 184: Novartis AG: assets & liabilities 271

To order this report:

Biotechnology Industry: Biotechnology: Global Industry Guide

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker